These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

184 related articles for article (PubMed ID: 16540672)

  • 1. Intrapulmonary administration of CCL21 gene-modified dendritic cells reduces tumor burden in spontaneous murine bronchoalveolar cell carcinoma.
    Yang SC; Batra RK; Hillinger S; Reckamp KL; Strieter RM; Dubinett SM; Sharma S
    Cancer Res; 2006 Mar; 66(6):3205-13. PubMed ID: 16540672
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Secondary lymphoid organ chemokine reduces pulmonary tumor burden in spontaneous murine bronchoalveolar cell carcinoma.
    Sharma S; Stolina M; Zhu L; Lin Y; Batra R; Huang M; Strieter R; Dubinett SM
    Cancer Res; 2001 Sep; 61(17):6406-12. PubMed ID: 11522634
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Interleukin-7 gene-modified dendritic cells reduce pulmonary tumor burden in spontaneous murine bronchoalveolar cell carcinoma.
    Sharma S; Batra RK; Yang SC; Hillinger S; Zhu L; Atianzar K; Strieter RM; Riedl K; Huang M; Dubinett SM
    Hum Gene Ther; 2003 Nov; 14(16):1511-24. PubMed ID: 14577913
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Intratumoral administration of dendritic cells overexpressing CCL21 generates systemic antitumor responses and confers tumor immunity.
    Yang SC; Hillinger S; Riedl K; Zhang L; Zhu L; Huang M; Atianzar K; Kuo BY; Gardner B; Batra RK; Strieter RM; Dubinett SM; Sharma S
    Clin Cancer Res; 2004 Apr; 10(8):2891-901. PubMed ID: 15102698
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Macrophage-derived chemokine gene transfer results in tumor regression in murine lung carcinoma model through efficient induction of antitumor immunity.
    Guo J; Wang B; Zhang M; Chen T; Yu Y; Regulier E; Homann HE; Qin Z; Ju DW; Cao X
    Gene Ther; 2002 Jun; 9(12):793-803. PubMed ID: 12040461
    [TBL] [Abstract][Full Text] [Related]  

  • 6. T cell-dependent antitumor immunity mediated by secondary lymphoid tissue chemokine: augmentation of dendritic cell-based immunotherapy.
    Kirk CJ; Hartigan-O'Connor D; Nickoloff BJ; Chamberlain JS; Giedlin M; Aukerman L; Mule JJ
    Cancer Res; 2001 Mar; 61(5):2062-70. PubMed ID: 11280767
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Herpes simplex virus (HSV) amplicon-mediated codelivery of secondary lymphoid tissue chemokine and CD40L results in augmented antitumor activity.
    Tolba KA; Bowers WJ; Muller J; Housekneckt V; Giuliano RE; Federoff HJ; Rosenblatt JD
    Cancer Res; 2002 Nov; 62(22):6545-51. PubMed ID: 12438249
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Dendritic cells augment granulocyte-macrophage colony-stimulating factor (GM-CSF)/herpes simplex virus thymidine kinase-mediated gene therapy of lung cancer.
    Miller PW; Sharma S; Stolina M; Chen K; Zhu L; Paul RW; Dubinett SM
    Cancer Gene Ther; 1998; 5(6):380-9. PubMed ID: 9917093
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Treatment of spontaneous metastatic lung cancer with tumor antigen-pulsed, interleukin-18 gene-modified dendritic cells].
    Chen J; Cao X; Xiu Q
    Zhonghua Yi Xue Za Zhi; 2001 Jul; 81(13):779-82. PubMed ID: 11798964
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Delivery of CCL21 to metastatic disease improves the efficacy of adoptive T-cell therapy.
    Thanarajasingam U; Sanz L; Diaz R; Qiao J; Sanchez-Perez L; Kottke T; Thompson J; Chester J; Vile RG
    Cancer Res; 2007 Jan; 67(1):300-8. PubMed ID: 17210711
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Persistent, antigen-specific, therapeutic antitumor immunity by dendritic cells genetically modified with an adenoviral vector to express a model tumor antigen.
    Song W; Tong Y; Carpenter H; Kong HL; Crystal RG
    Gene Ther; 2000 Dec; 7(24):2080-6. PubMed ID: 11223988
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Synergistic antitumor effect by coexpression of chemokine CCL21/SLC and costimulatory molecule LIGHT.
    Hisada M; Yoshimoto T; Kamiya S; Magami Y; Miyaji H; Yoneto T; Tamada K; Aoki T; Koyanagi Y; Mizuguchi J
    Cancer Gene Ther; 2004 Apr; 11(4):280-8. PubMed ID: 15002032
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Route of administration influences the antitumor effects of bone marrow-derived dendritic cells engineered to produce interleukin-12 in a metastatic mouse prostate cancer model.
    Saika T; Satoh T; Kusaka N; Ebara S; Mouraviev VB; Timme TL; Thompson TC
    Cancer Gene Ther; 2004 May; 11(5):317-24. PubMed ID: 15044961
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Generation of anti-tumor response by JAWS II mouse dendritic cells transduced with murine interleukin 12 genes.
    Pajtasz-Piasecka E; Rossowska J; Szyda A; Krawczenko A; Dus D
    Oncol Rep; 2007 May; 17(5):1249-57. PubMed ID: 17390073
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Anti-metastatic effect of vascular endothelial growth factor receptor 2 extracellular domain gene-modified dendritic cell vaccination in murine model with experimental pulmonary metastasis].
    Pan JP; Weng YS; Wu QQ
    Zhonghua Zhong Liu Za Zhi; 2006 Sep; 28(9):646-9. PubMed ID: 17274366
    [TBL] [Abstract][Full Text] [Related]  

  • 16. CCL19 reduces tumour burden in a model of advanced lung cancer.
    Hillinger S; Yang SC; Batra RK; Strieter RM; Weder W; Dubinett SM; Sharma S
    Br J Cancer; 2006 Apr; 94(7):1029-34. PubMed ID: 16598185
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Dendritic cells modified to express fractalkine/CX3CL1 in the treatment of preexisting tumors.
    Nukiwa M; Andarini S; Zaini J; Xin H; Kanehira M; Suzuki T; Fukuhara T; Mizuguchi H; Hayakawa T; Saijo Y; Nukiwa T; Kikuchi T
    Eur J Immunol; 2006 Apr; 36(4):1019-27. PubMed ID: 16525992
    [TBL] [Abstract][Full Text] [Related]  

  • 18. HER-2/neu-gene engineered dendritic cell vaccine stimulates stronger HER-2/neu-specific immune responses compared to DNA vaccination.
    Chan T; Sami A; El-Gayed A; Guo X; Xiang J
    Gene Ther; 2006 Oct; 13(19):1391-402. PubMed ID: 16724093
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficient induction of specific cytotoxic T lymphocytes to tumor rejection peptide using functional matured 2 day-cultured dendritic cells derived from human monocytes.
    Tanaka F; Yamaguchi H; Haraguchi N; Mashino K; Ohta M; Inoue H; Mori M
    Int J Oncol; 2006 Nov; 29(5):1263-8. PubMed ID: 17016660
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Combined HSV-TK/GCV and secondary lymphoid tissue chemokine gene therapy inhibits tumor growth and elicits potent antitumor CTL response in tumor-bearing mice.
    Warren P; Song W; Holle E; Holmes L; Wei Y; Li J; Wagner T; Yu X
    Anticancer Res; 2002; 22(2A):599-604. PubMed ID: 12014627
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.